Probi AB (publ)

Probi AB (publ) specializes in the research, development, manufacturing, marketing, and distribution of probiotics for the health, pharmaceutical, and food sectors. The company's scientific endeavors primarily focus on areas such as gastrointestinal, digestive, immune, and bone health, as well as iron absorption, and the specific health requirements of children, women, and seniors. Their product range includes dietary supplements and various food and beverage applications, offered in diverse formats like capsules, tablets (including chewable), spheres, powders, and an array of drinks such as fruit drinks, shots, carbonated beverages, and recovery drinks. Probi's products are sold in approximately 40 countries globally. The company also fosters collaborations, including a partnership with Örebro University for exploring needle-free vaccines and with La Trobe University for a clinical trial assessing the effects of Probi Osteo in Australian women. Established in 1991 and headquartered in Lund, Sweden, Probi AB (publ) operates as a subsidiary of Symrise AG.

Probi AB (publ) trades as PROB.ST on STO. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in SEK.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Probi AB (publ) can be compared against peers such as Abliva AB (publ), AroCell AB (publ), Elos Medtech AB (publ), Emplicure AB (publ), InDex Pharmaceuticals Holding AB (publ), Lipidor AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $3.97B, beta of 0.46, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

PROB.ST currently shows total debt of N/A and beta of 0.46. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.probi.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.